Alto Neuroscience (ANRO) Free Cash Flow (2023 - 2026)

Alto Neuroscience has reported Free Cash Flow for 4 years, with the latest figure at -$28.0 million in Q1 2026.

• Quarterly Free Cash Flow fell 69.07% year-over-year to -$28.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$63.2 million (down 19.79% YoY) and the FY2025 annual result came in at -$51.8 million, down 9.21% from the prior year.
• Free Cash Flow fell to -$28.0 million in Q1 2026 per ANRO's latest filing, from -$11.5 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$6.7 million in Q2 2023 and troughed at -$28.0 million in Q1 2026.
• A 4-year average of -$12.4 million and a median of -$11.5 million in 2025 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow slumped 79.34% in 2024, then climbed 11.4% in 2025.
• Over 4 years, Free Cash Flow stood at -$12.0 million in 2023, then dropped by 8.3% to -$13.0 million in 2024, then advanced by 11.34% to -$11.5 million in 2025, then sank by 143.42% to -$28.0 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$28.0 million, -$11.5 million, and -$9.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.